Literature DB >> 16294210

Overexpression of the antiapoptotic protein A1 promotes the survival of double positive thymocytes awaiting positive selection.

C Verschelde1, D Michonneau, M-C Trescol-Biemont, I Berberich, A Schimpl, N Bonnefoy-Berard.   

Abstract

As it has been shown for Mcl-1, Bcl-xl and Bcl-2, proteins of the Bcl-2 family play a crucial role during T-cell development in the thymus. We here show that the expression of the antiapoptotic gene A1 is specifically enhanced at the DN3/DN4 transition and in DP thymocytes that have been positively selected suggesting that A1 expression might be considered as a transcriptional signature of thymocytes that have received pre-TCR or TCR survival signal. Furthermore, we observed that A1-a overexpression in recombination activation gene 1-deficient mice transgenic for the major histocompatibillity complex class I-restricted F5 TCR enhances cell survival of DP thymocytes and permits accumulation of DP cells awaiting positive selection. However, A1-a overexpression has no effect on negative selection. Therefore, our results suggest that A1 plays a specialized role in allowing survival of DP thymocytes and that its role can be distinguished from that of Mcl-1, Bcl-xl and Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16294210     DOI: 10.1038/sj.cdd.4401814

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  12 in total

Review 1.  BCL2A1: the underdog in the BCL2 family.

Authors:  M Vogler
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment.

Authors:  Robyn L Schenk; Selma Tuzlak; Emma M Carrington; Yifan Zhan; Susanne Heinzel; Charis E Teh; Daniel H Gray; Lin Tai; Andrew M Lew; Andreas Villunger; Andreas Strasser; Marco J Herold
Journal:  Cell Death Differ       Date:  2017-01-13       Impact factor: 15.828

Review 3.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 4.  The essential role of evasion from cell death in cancer.

Authors:  Gemma L Kelly; Andreas Strasser
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

5.  c-Myb promotes the survival of CD4+CD8+ double-positive thymocytes through upregulation of Bcl-xL.

Authors:  Joan Yuan; Rowena B Crittenden; Timothy P Bender
Journal:  J Immunol       Date:  2010-02-08       Impact factor: 5.422

6.  Molecular correlates of experimental cerebral malaria detectable in whole blood.

Authors:  Miranda S Oakley; Vivek Anantharaman; Thiago M Venancio; Hong Zheng; Babita Mahajan; Victoria Majam; Thomas F McCutchan; Timothy G Myers; L Aravind; Sanjai Kumar
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

7.  Cutting Edge: Ikaros null thymocytes mature into the CD4 lineage with reduced TCR signal: A study using CD3{zeta} immunoreceptor tyrosine-based activation motif transgenic mice.

Authors:  Julie A Urban; William Brugmann; Susan Winandy
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

8.  Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection.

Authors:  K J Campbell; D H D Gray; N Anstee; A Strasser; S Cory
Journal:  Cell Death Differ       Date:  2012-06-29       Impact factor: 15.828

9.  Interleukin-7 supports survival of T-cell receptor-β-expressing CD4(-) CD8(-) double-negative thymocytes.

Authors:  Juan Xiong; Brooks L Parker; Stacy L Dalheimer; Thomas M Yankee
Journal:  Immunology       Date:  2013-04       Impact factor: 7.397

Review 10.  A1/Bfl-1 in leukocyte development and cell death.

Authors:  Eleonora Ottina; Denise Tischner; Marco J Herold; Andreas Villunger
Journal:  Exp Cell Res       Date:  2012-02-04       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.